Multidrug-resistant breast cancer: current perspectives

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• AhmadAPathways to breast cancer recurrenceISRN Oncology2013201316
   Google Scholar
• MusgroveEASutherlandRLBiological determinants of endocrine resistance in breast cancerNat Rev Cancer20099963164319701242
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMorales-VasquezFHortobagyiGOverview of resistance to systemic therapy in patients with breast cancerYuDHungM-CBreast Cancer Chemosensitivity608New YorkSpringer2007122
   Google Scholar
• ParkinDMPisaniPFerlayJGlobal cancer statisticsCA Cancer J Clin1999491336410200776
   PubMed Web of Science ®Google Scholar
• GuiuSMichielsSAndreFMolecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group StatementAnn Oncol201223122997300623166150
   PubMed Web of Science ®Google Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• CurtisCShahSPChinS-FThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature2012486740334635222522925
   PubMed Web of Science ®Google Scholar
• BiancoSGevryNEndocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanismsTranscription20123416517022771991
   PubMedGoogle Scholar
• PohlmannPRMayerIAMernaughRResistance to trastuzumab in breast cancerClin Cancer Res200915247479749120008848
   PubMed Web of Science ®Google Scholar
• VuTClaretFXTrastuzumab: updated mechanisms of action and resistance in breast cancerFront Oncol201226222720269
   PubMedGoogle Scholar
• ChenKGSikicBIMolecular pathways: regulation and therapeutic implications of multidrug resistanceClin Cancer Res20121871863186922344233
   PubMed Web of Science ®Google Scholar
• LimEMetzger-FilhoOWinerEPThe natural history of hormone receptor-positive breast cancerOncology (Williston Park)201226868869469622957400
   PubMed Web of Science ®Google Scholar
• BriskenCProgesterone signalling in breast cancer: a neglected hormone coming into the limelightNat Rev Cancer201313638539623702927
   PubMed Web of Science ®Google Scholar
• BjörnströmLSjöbergMMechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genesMol Endocrinol200519483384215695368
   PubMedGoogle Scholar
• MadeiraMMattarALogulloAFSoaresFAGebrimLHEstrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness – a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancerBMC Cancer201313142524047421
   PubMed Web of Science ®Google Scholar
• HaldosénL-AZhaoCDahlman-WrightKEstrogen receptor beta in breast cancerMol Cell Endocrinol Epub8152013
   Google Scholar
• Garcia-BecerraRSantosNDiazLCamachoJMechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistanceInt J Mol Sci201214110814523344024
   PubMed Web of Science ®Google Scholar
• DestaZWardBASoukhovaNVFlockhartDAComprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6J Pharmacol Exp Ther200431031062107515159443
   PubMed Web of Science ®Google Scholar
• ParkinsonABiotransformation of xenobioticsKlaassenCDCasarett and Doull’s Toxicology: The Basic Science of Poisons6th edNew YorkMcGraw Hill2001187188
   Google Scholar
• TanSHLeeSCGohBCWongJPharmacogenetics in breast cancer therapyClin Cancer Res200814248027804119088019
   PubMed Web of Science ®Google Scholar
• BrauchHSchwabMPrediction of tamoxifen outcome by genetic variation of CYP2D6 in postmenopausal women with early breast cancerBr J Clin Pharmacol Epub8222013
   Web of Science ®Google Scholar
• TabaKKuramitsuYRyozawaSHeat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cellsAnticancer Res20103072539254320682980
   PubMed Web of Science ®Google Scholar
• ZwartWGriekspoorAKuijlCSpatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escapeImmunity200522222123315723810
   PubMed Web of Science ®Google Scholar
• WangR-AMazumdarAVadlamudiRKKumarRP21-activated kinase-1 phosphorylates and transactivates estrogen receptor-[alpha] and promotes hyperplasia in mammary epitheliumEMBO J200221205437544712374744
   PubMed Web of Science ®Google Scholar
• ZwartWGriekspoorABernoVPKA-induced resistance to tamoxifen is associated with an altered orientation of ERα towards co-activator SRC-1EMBO J200726153534354417627277
   PubMed Web of Science ®Google Scholar
• WangZZhangXShenPLoggieBWChangYDeuelTFA variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signalingProc Natl Acad Sci U S A2006103249063906816754886
   PubMed Web of Science ®Google Scholar
• LiGZhangJJinKEstrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cellsMol Oncol20137361162423499324
   PubMed Web of Science ®Google Scholar
• ShiLDongBLiZExpression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancerJ Clin Oncol200927213423342919487384
   PubMed Web of Science ®Google Scholar
• SunMPacigaJEFeldmanRIPhosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3KCancer Res200161165985599111507039
   PubMed Web of Science ®Google Scholar
• HennessyBTSmithDLRamPTLuYMillsGBExploiting the PI3K/AKT pathway for cancer drug discoveryNat Rev Drug Discov2005412988100416341064
   PubMed Web of Science ®Google Scholar
• TomlinsonDCKnowlesMASpeirsVMechanisms of FGFR3 actions in endocrine resistant breast cancerInt J Cancer2012130122857286621792889
   PubMed Web of Science ®Google Scholar
• FoxEMMillerTWBalkoJMA kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancerCancer Res201171216773678421908557
   PubMed Web of Science ®Google Scholar
• SachdevaMWuHRuPHwangLTrieuVMoYYMicroRNA-101-mediated Akt activation and estrogen-independent growthOncogene201130782283120956939
   PubMed Web of Science ®Google Scholar
• SvotelisABiancoSMadoreJH3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERalpha ligand dependencyEMBO J201130193947396121841772
   PubMed Web of Science ®Google Scholar
• FiszmanGLJasnisMAMolecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancerInt J Breast Cancer2011201135218222295219
   PubMedGoogle Scholar
• NahtaRO’ReganRMTherapeutic implications of estrogen receptor signaling in HER2-positive breast cancersBreast Cancer Res Treat20121351394822527112
   PubMed Web of Science ®Google Scholar
• HudisCATrastuzumab: mechanism of action and use in clinical practiceN Engl J Med20073571395117611206
   PubMed Web of Science ®Google Scholar
• NagyPFriedlanderETannerMDecreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell lineCancer Res200565247348215695389
   PubMed Web of Science ®Google Scholar
• Palyi-KrekkZBarokMIsolaJTammiMSzollosiJNagyPHyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancerEur J Cancer200743162423243317911008
   PubMed Web of Science ®Google Scholar
• GajriaDChandarlapatySHER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Rev Anticancer Ther201111226327521342044
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJHER2 therapy: molecular mechanisms of trastuzumab resistanceBreast Cancer Res20068621517096862
   PubMed Web of Science ®Google Scholar
• LuYZiXZhaoYMascarenhasDPollakMInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst200193241852185711752009
   PubMed Web of Science ®Google Scholar
• ShattuckDLMillerJKCarrawayKL3rdSweeneyCMet receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cellsCancer Res20086851471147718316611
   PubMed Web of Science ®Google Scholar
• GongCYaoYWangYUp-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancerJ Biol Chem201128621191271913721471222
   PubMed Web of Science ®Google Scholar
• ChakrabartyABholaNESuttonCTrastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitorsCancer Res20137331190120023204226
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo cytotoxicity against tumor targetsNat Med20006444344610742152
   PubMed Web of Science ®Google Scholar
• MusolinoANaldiNBortesiBImmunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancerJ Clin Oncol200826111789179618347005
   PubMed Web of Science ®Google Scholar
• BoylePTriple-negative breast cancer: epidemiological considerations and recommendationsAnn Oncol201223Suppl. 6vi7vi1223012306
   PubMed Web of Science ®Google Scholar
• HudisCAGianniLTriple-negative breast cancer: an unmet medical needOncologist201116Suppl 111121278435
   PubMed Web of Science ®Google Scholar
• AbalMAndreuJMBarasoainITaxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of actionCurr Cancer Drug Targets20033319320312769688
   PubMed Web of Science ®Google Scholar
• ThornCFOshiroCMarshSDoxorubicin pathways: pharmacodynamics and adverse effectsPharmacogenet Genomics201121744044621048526
   PubMed Web of Science ®Google Scholar
• ClarkeRLeonessaFTrockBMultidrug resistance/p-glycoprotein and breast cancer: review and meta-analysisSemin Oncol2005326 Suppl 7915
   PubMed Web of Science ®Google Scholar
• WindNSHolenIMultidrug resistance in breast cancer: from in vitro models to clinical studiesInt J Breast Cancer2011201196741922332018
   PubMedGoogle Scholar
• TeftWAMansellSEKimRBEndoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)Drug Metab Dispos201139355856221148080
   PubMed Web of Science ®Google Scholar
• KutanziKRYurchenkoOVBelandFACheckhunVFPogribnyIPMicroRNA-mediated drug resistance in breast cancerClin Epigenetics20112217118521949547
   PubMed Web of Science ®Google Scholar
• LinXZhangXWangQPerifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-kappaB signaling pathway in a human breast cancer cell lineNeoplasma201259324825622329846
   PubMed Web of Science ®Google Scholar
• ChekhunVFKulikGIYurchenkoOVRole of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cellsCancer Lett20062311879316356834
   PubMed Web of Science ®Google Scholar
• SharmaGMirzaSParshadRCpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patientsClin Biochem2010434–537337919879256
   PubMed Web of Science ®Google Scholar
• TothMBorosIMBalintEElevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cellsCancer Sci2012103465966922320423
   PubMed Web of Science ®Google Scholar
• GruntTWMarianiGLNovel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signalingCurr Cancer Drug Targets201313218820423215720
   PubMed Web of Science ®Google Scholar
• FaraziTAHoellJIMorozovPTuschlTMicroRNAs in human cancerAdv Exp Med Biol201377412023377965
   PubMed Web of Science ®Google Scholar
• ChenKRajewskyNThe evolution of gene regulation by transcription factors and microRNAsNat Rev Genet2007829310317230196
   PubMed Web of Science ®Google Scholar
• ChenGQZhaoZWZhouHYLiuYJYangHJSystematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicinMed Oncol201027240641519412672
   PubMed Web of Science ®Google Scholar
• FrankelLBChristoffersenNRJacobsenALindowMKroghALundAHProgrammed cell death 4 (PDCD4) Is an important functional target of the MicroRNA miR-21 in breast cancer cellsJ Biol Chem200828321026103317991735
   PubMed Web of Science ®Google Scholar
• NassirpourRMehtaPPBaxiSMYinMJmiR-221 promotes tumorigenesis in human triple negative breast cancer cellsPLoS One201384e6217023637992
   PubMed Web of Science ®Google Scholar
• CalnanDRBrunetAThe FoxO codeOncogene200827162276228818391970
   PubMed Web of Science ®Google Scholar
• MehtaRJJainRKLeungSFOXA1 is an independent prognostic marker for ER-positive breast cancerBreast Cancer Res Treat2012131388189021503684
   PubMed Web of Science ®Google Scholar
• IjichiNIkedaKHorie-InoueKInoueSFOXP1 and estrogen signaling in breast cancerVitam Horm20139320321223810008
   PubMed Web of Science ®Google Scholar
• CarrJRParkHJWangZKieferMMRaychaudhuriPFoxM1 mediates resistance to herceptin and paclitaxelCancer Res201070125054506320530690
   PubMed Web of Science ®Google Scholar
• ChoiHKChoKBPhuongNTSIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cellsMol Pharm20131072517252723763570
   PubMed Web of Science ®Google Scholar
• MaieseKChongZZShangYCHouJClever cancer strategies with FoxO transcription factorsCell Cycle20087243829383919066462
   PubMed Web of Science ®Google Scholar
• ZouYTsaiWBChengCJForkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesisBreast Cancer Res2008101R2118312651
   PubMed Web of Science ®Google Scholar
• AnnunziatoADNA packaging: nucleosomes and chromatinNature Education200811
   Google Scholar
• SvotelisAGevryNGrondinGGaudreauLH2A.Z overexpression promotes cellular proliferation of breast cancer cellsCell Cycle20109236437020023423
   PubMed Web of Science ®Google Scholar
• HolmKGrabauDLövgrenKGlobal H3K27 trimethylation and EZH2 abundance in breast tumor subtypesMol Oncol20126549450622766277
   PubMed Web of Science ®Google Scholar
• MishraSKMandalMMazumdarAKumarRDynamic chromatin remodeling on the HER2 promoter in human breast cancer cellsFEBS Letters20015071889411682064
   PubMed Web of Science ®Google Scholar
• JonesPABaylinSBThe epigenomics of cancerCell2007128468369217320506
   PubMed Web of Science ®Google Scholar
• PhuongNTKimSKLimSCRole of PTEN promoter methylation in tamoxifen-resistant breast cancer cellsBreast Cancer Res Treat20111301738321170675
   PubMed Web of Science ®Google Scholar
• HervouetECartronPFJouvenotMDelage-MourrouxREpigenetic regulation of estrogen signaling in breast cancerEpigenetics20138323724523364277
   PubMed Web of Science ®Google Scholar
• RheeJKKimKChaeHIntegrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancerNucleic Acids Res201341188464847423887935
   PubMed Web of Science ®Google Scholar
• NetworkTCGComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• NobiliSLandiniIMazzeiTMiniEOvercoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expressionMed Res Rev20123261220126221374643
   PubMed Web of Science ®Google Scholar
• BaderAGLammersPThe therapeutic potential of microRNAsInnovations in Pharmaceutical Technology20115255
   Google Scholar
• BroderickJAZamorePDMicroRNA therapeuticsGene Ther201118121104111021525952
   PubMed Web of Science ®Google Scholar
• van RooijEPurcellALLevinAADeveloping microRNA therapeuticsCirc Res2012110349650722302756
   PubMed Web of Science ®Google Scholar
• LinaresADalencFBalaguerPBoulleNCavaillesVManipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?J Biomed Biotechnol2011201185698521188173
   PubMedGoogle Scholar
• TateCRRhodesLVSegarHCTargeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostatBreast Cancer Res2012143R7922613095
   PubMed Web of Science ®Google Scholar
• HuangXWangSLeeCKYangXLiuBHDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistanceCancer Lett20113071727921497990
   PubMed Web of Science ®Google Scholar
• BayraktarSGlückSMolecularly targeted therapies for metastatic triple-negative breast cancerBreast Cancer Res Treat20131381213523358903
   PubMed Web of Science ®Google Scholar
• LvKLiuLWangLLin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cellsPLoS One201277e4000822808086
   PubMed Web of Science ®Google Scholar
• ManavalanTTTengYAppanaSNDifferential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY 2 human breast cancer cellsCancer Lett20113131264321955614
   PubMed Web of Science ®Google Scholar
• NiuJShiYTanGDNA damage induces NF-kappaB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasionJ Biol Chem201228726217832179522547075
   PubMed Web of Science ®Google Scholar
• ZhongSLiWChenZXuJZhaoJmiR-222 and miR-29a contribute to the drug-resistance of breast cancer cellsGene2013531181423994196
   PubMed Web of Science ®Google Scholar
• BockhornJDaltonRNwachukwuCMicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11Nat Commun20134139323340433
   PubMed Web of Science ®Google Scholar
• KornerCKeklikoglouIBenderCWornerAMunstermannEWiemannSMicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon)J Biol Chem2013288128750876123364795
   PubMed Web of Science ®Google Scholar
• LiXJJiMHZhongSLMicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1Arch Med Res201243751452123085450
   PubMed Web of Science ®Google Scholar
• WangHTanGDongLCirculating MiR-125b as a marker predicting chemoresistance in breast cancerPLoS One201274e3421022523546
   PubMed Web of Science ®Google Scholar
• ZhuYYuFJiaoYReduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5Clin Cancer Res201117227105711521953503
   PubMed Web of Science ®Google Scholar
• ZhuXLiYShenHmiR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1Acta Biochim Biophys Sin (Shanghai)2013452808623178914
   PubMed Web of Science ®Google Scholar
• JiaoXZhaoLMaMMiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)Breast Cancer Res Treat2013139371773023780685
   PubMed Web of Science ®Google Scholar
• ManavalanTTTengYLitchfieldLMMuluhngwiPAl-RayyanNKlingeCMReduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cellsPLoS One201384e6233423626803
   PubMed Web of Science ®Google Scholar
• KoppFOakPSWagnerERoidlAmiR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expressionPLoS One2012711e5046923209748
   PubMed Web of Science ®Google Scholar
• RuPSteeleRHsuehECRayRBAnti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivityGenes Cancer20112772072722207897
   PubMedGoogle Scholar
• JungEJSantarpiaLKimJPlasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patientsCancer2012118102603261422370716
   PubMed Web of Science ®Google Scholar
• BaoLHazariSMehraSKaushalDMorozKDashSIncreased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298Am J Pathol201218062490250322521303
   PubMed Web of Science ®Google Scholar
• WardABalwierzAZhangJDRe-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancerOncogene20133291173118222508479
   PubMed Web of Science ®Google Scholar
• MaMTHeMWangYMiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2)Cancer Lett2013339110711523879965
   PubMed Web of Science ®Google Scholar
• YamamotoYYoshiokaYMinouraKAn integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cellsMol Cancer20111013522051041
   PubMed Web of Science ®Google Scholar
• HuHLiSCuiXThe overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2)J Biol Chem201328816109731098523436656
   PubMed Web of Science ®Google Scholar
• ReedKHembruffSLLabergeMLVilleneuveDJCoteGBParissentiAMHypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cellsEpigenetics20083527028019001875
   PubMed Web of Science ®Google Scholar
• ReedKHembruffSLSprowlJAParissentiAMThe temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistancePharmacogenomics J201010648950420125118
   PubMed Web of Science ®Google Scholar
• BoettcherMKischkelFHoheiselJDHigh-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistancePLoS One201056e1100220544021
   PubMed Web of Science ®Google Scholar
• HuangCCaoPXieZRelation of promoter methylation of mdr-1 gene and histone acetylation status with multidrug resistance in MCF-7/Adr cellsZhong Nan Da Xue Xue Bao Yi Xue Ban200934536937419483282
   PubMedGoogle Scholar
• ChekhunVFLukyanovaNYKovalchukOTryndyakVPPogribnyIPEpigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targetsMol Cancer Ther2007631089109817363502
   PubMed Web of Science ®Google Scholar
• IornsETurnerNCElliottRIdentification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancerCancer Cell20081329110418242510
   PubMed Web of Science ®Google Scholar
• ChangHGKimSJChungKWTamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha geneJ Mol Med (Berl)200583213213915536519
   PubMed Web of Science ®Google Scholar
• AltundagOAltundagKGunduzMDNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patientsMed Hypotheses200463468468715325017
   PubMed Web of Science ®Google Scholar
• RaguzSAdamsCMasrourNLoss of O(6)-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cellsBiochem Pharmacol201385218619623122841
   PubMed Web of Science ®Google Scholar
• KimSJKangHSJungSYMethylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissuesJ Mol Med (Berl)201088111123113120628863
   PubMed Web of Science ®Google Scholar
• VijayaraghavaluSDermawanJKCheriyathVLabhasetwarVHighly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrestMol Pharm201310133735223215027
   PubMed Web of Science ®Google Scholar
• WargonVFernandezSVGoinMGiulianelliSRussoJLanariCHypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomasBreast Cancer Res Treat2011126231933220440553
   PubMed Web of Science ®Google Scholar
• StoneAValdes-MoraFGeeJMTamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerPLoS One201277e4046622808167
   PubMed Web of Science ®Google Scholar
• MartensJWMNimmrichIKoenigTAssociation of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancerCancer Res200565104101411715899800
   PubMed Web of Science ®Google Scholar
• ShanJMasonJMYuanLRab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cellsGene20002571677511054569
   PubMed Web of Science ®Google Scholar
• TianKWangYHuangYSunBLiYXuHMethylation of WTH3, a possible drug resistant gene, inhibits p53 regulated expressionBMC Cancer2008832718992151
   PubMed Web of Science ®Google Scholar
• YangRLiWWHoangBHQuantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrierBMC Cancer2008812418452618
   PubMed Web of Science ®Google Scholar